4//SEC Filing
Donadio Jamie A 4
Accession 0001214659-18-001759
CIK 0001576263other
Filed
Mar 1, 7:00 PM ET
Accepted
Mar 2, 6:08 PM ET
Size
20.8 KB
Accession
0001214659-18-001759
Insider Transaction Report
Form 4
Donadio Jamie A
VP of Finance
Transactions
- Exercise/Conversion
Common Stock
2018-03-01$5.50/sh+9,375$51,563→ 9,375 total - Exercise/Conversion
Common Stock
2018-03-01$5.40/sh+12,500$67,500→ 21,875 total - Exercise/Conversion
Common Stock
2018-03-01$7.30/sh+30,000$219,000→ 51,875 total - Sale
Common Stock
2018-03-01$26.78/sh−25,600$685,514→ 26,275 total - Sale
Common Stock
2018-03-01$27.45/sh−25,775$707,591→ 500 total - Sale
Common Stock
2018-03-01$28.08/sh−500$14,040→ 0 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-03-01−9,375→ 20,625 totalExercise: $5.50Exp: 2026-10-26→ Common Stock (9,375 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-03-01−12,500→ 37,500 totalExercise: $5.40Exp: 2027-01-25→ Common Stock (12,500 underlying) - Exercise/Conversion
Employee Stock Option (Right to Buy)
2018-03-01−30,000→ 0 totalExercise: $7.30Exp: 2020-03-19→ Common Stock (30,000 underlying)
Footnotes (6)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2017.
- [F2]1/4th of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.
- [F3]Twenty percent (20%) of the shares subject to the stock option vested and became exercisable on the grant date of the option (March 20, 2013), and an additional 20% shall vest and become exercisable each year on the anniversary of the grant date.
- [F4]This transaction was executed in multiple trades at prices ranging from $26.05 to $27.025. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $27.05 to $28.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F6]This transaction was executed in multiple trades at prices ranging from $28.05 to $28.20. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Documents
Issuer
Mirati Therapeutics, Inc.
CIK 0001576263
Entity typeother
Related Parties
1- filerCIK 0001579771
Filing Metadata
- Form type
- 4
- Filed
- Mar 1, 7:00 PM ET
- Accepted
- Mar 2, 6:08 PM ET
- Size
- 20.8 KB